Report: Hong Kong's dividend payout is expected to reach $25.5 billion by 2025 with core dividends increasing by 8.5%.
In 2025, Hong Kong's dividend payout exceeded the high level of 2017, reaching $25.5 billion, with core dividend growth of 8.5%. The core growth rate in the fourth quarter was 4.3%, with the financial industry contributing about one-third of the growth.
Capital Group recently released its "Dividend Watch" report, forecasting that the global dividend total will reach $2.09 trillion by 2025, a 7.0% year-on-year increase and a new annual high. Adjusted for exchange rates, one-off payments, and calendar factors, core dividend growth is at 6.0%. At the company level, the median dividend growth is 5.8%. Dividends in Hong Kong reached a high of $25.5 billion, with core dividend growth at 8.5%. The fourth quarter core growth rate is 4.3%, with the financial sector contributing about one-third of the growth.
The report states that dividend payments in China have been significantly affected by major calendar adjustments, with more Chinese companies splitting traditional annual one-time dividends into two smaller payments. This factor alone has increased the total annual dividend amount by nearly $4 billion, offsetting the lower special dividend in the total growth rate.
The report shows that the global dividend total is expected to rise to $2.2 trillion by 2026. For investors in Hong Kong and mainland China, dividends can continue to provide a reliable source of income and resilience in different market conditions.
Vivian Chan, Head of Client Business for Capital Group in Hong Kong and Greater China, stated that dividends are one of the most tangible ways for companies to share their success with investors. In the current environment of geopolitical uncertainty, trade tensions, and market volatility, companies that consistently pay dividends and demonstrate sustainable growth can provide stability to investment portfolios.
Related Articles

Chongqing Zhifei Biological Products (300122.SZ): HK.3-JN.1 COVID-19 mRNA vaccine approved for clinical trials.

Wuxi Delinhai Environmental Technology's net profit attributable to parent company for the year 2025 was 52.3075 million yuan, turning losses into gains year-on-year.

Citibank: TRIP.COM-S (09961) reports healthy fourth quarter performance. Revenue beats expectations but operating profit margin slightly underperforms.
Chongqing Zhifei Biological Products (300122.SZ): HK.3-JN.1 COVID-19 mRNA vaccine approved for clinical trials.

Wuxi Delinhai Environmental Technology's net profit attributable to parent company for the year 2025 was 52.3075 million yuan, turning losses into gains year-on-year.

Citibank: TRIP.COM-S (09961) reports healthy fourth quarter performance. Revenue beats expectations but operating profit margin slightly underperforms.

RECOMMEND

Robot Concept Hong Kong Stocks Retreat After Spring Gala Rally As 2026 Emerges As Pivotal Year For Mass Production And Commercialization
25/02/2026

Hong Kong IPO Fundraising Surges Tenfold At Start Of Year As 110 A‑Share Companies Queue For Listings
25/02/2026

AI Iteration Risks Surface As Hong Kong Market Diverges; Low‑Valuation, High‑Dividend Legacy Stocks Attract Capital As Safe Havens
25/02/2026


